Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals reported a net loss of $32.7 million for the second quarter of 2026, bringing the six-month net loss to $53.5 million. The company's cash, cash equivalents, and marketable securities stood at $110.2 million as of June 30, 2026, with an accumulated deficit of $499.9 million. Management raised substantial doubt about the company's ability to continue as a going concern, citing expected additional losses and the need for further capital. Despite financial challenges, Acumen continues to advance its sabirnetug Phase 2 ALTITUDE-AD clinical trial, with top-line results anticipated in late 2026, and nominated two EBD development candidates in June 2026.

Acumen Pharmaceuticals reported a Q2 2026 net loss of $32.7 million, or $(0.45) per share, an improvement from a net loss of $41.0 million, or $(0.68) per share, in Q2 2025. The company's cash, cash equivalents, and marketable securities stood at $110.2 million as of June 30, 2026, expected to fund operations into early 2027. Key business highlights include anticipated topline results for the ALTITUDE-AD Phase 2 study in late 2026 and targeting a mid-2027 IND filing for a lead candidate in its Enhanced Brain Delivery™ program.

Acumen Pharmaceuticals, Inc. announced it will report its second quarter financial results on Wednesday, August 12, 2026. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. Interested parties are advised to register in advance for the call, and an archived webcast will be available for 30 days.

Acumen Pharmaceuticals announced new findings at AAIC 2026, demonstrating significantly improved brain penetration of their EBD bispecific antibodies, particularly candidate ACU401, in non-human primates. This collaboration with JCR Pharmaceuticals showed up to 40-fold greater frontal cortex exposure and no hematological safety signals. Additionally, patient experience data from the ALTITUDE-AD trial underscored the unmet needs in early Alzheimer's disease, reinforcing the importance of Acumen's therapeutic development.

Acumen Pharmaceuticals announced the nomination of two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for the treatment of Alzheimer's disease. This follows the exercise of an option under its collaboration agreement with JCR Pharmaceuticals, leveraging JCR's J-Brain Cargo technology with Acumen's A O-selective antibodies. Preclinical studies demonstrated significantly enhanced brain penetration (14-40x higher antibody levels in NHPs), a low risk of anemia, and suitability for subcutaneous dosing, with IND submission targeted for mid-2027.

Acumen Pharmaceuticals reported a narrowed net loss for Q1 2026, reaching $(20.7) million compared to $(28.8) million in the prior year, driven by reduced R&D and operating expenses. The company also completed a private placement, raising approximately $35.7 million in gross proceeds. Despite these positive developments, Acumen disclosed substantial doubt about its ability to continue as a going concern, as current cash and equivalents may not be sufficient to fund operations for the next 12 months.

Acumen Pharmaceuticals reported a Q1 2026 net loss of $(20.7) million, an improvement from $(28.8) million in Q1 2025, with R&D expenses decreasing to $16.5 million. The company's cash, cash equivalents, and marketable securities increased to $128.4 million as of March 31, 2026, following a $35.75 million private placement, extending its cash runway into early 2027. Key clinical milestones include expected topline results for the Phase 2 ALTITUDE-AD study of sabirnetug in late 2026 and an IND filing for a lead EBD program candidate targeted for mid-2027.

Acumen Pharmaceuticals reported its first quarter 2026 financial results, showing a reduced net loss of $20.7 million and decreased R&D expenses. The company provided a business update, highlighting the anticipated topline results for its ALTITUDE-AD Phase 2 study in late 2026, which is investigating sabirnetug for early Alzheimer’s disease. Additionally, Acumen plans to file an IND for a lead clinical candidate in its EBD program by mid-2027 and expects to license two EBD candidates in Q2 2026. The company's cash balance of $128.4 million as of March 31, 2026, is projected to fund operations into early 2027.

Acumen Pharmaceuticals, Inc. announced that its management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference. The event is scheduled for May 14, 2026, and a live webcast will be accessible via the company's investor relations website. Acumen is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's disease, with its lead candidate sabirnetug currently in a Phase 2 clinical trial.

Acumen Pharmaceuticals, Inc. announced it will report its first-quarter financial results on Tuesday, May 12, 2026. Following the release, the company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. Interested parties are required to register in advance for the call, and an archived webcast will be available on the company's investor relations website.